Literature DB >> 22155674

Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma.

R A de Jong1, N L Toppen, K A Ten Hoor, H M Boezen, I P Kema, H Hollema, H W Nijman.   

Abstract

OBJECTIVE: It is generally recognized that the immune system has an important role in regulating cancer development. Evidence indicating a prognostic role of the immune system in vulvar carcinoma is scarce. This study investigated the presence and prognostic significance of several aspects of the immune system in vulvar squamous carcinoma.
METHODS: The number of intratumoral CD8(+) and Foxp3(+) T-lymphocytes, next to HLA class I (HLA-A, HLA-B/C and β(2)-m) and indoleamine 2,3-dioxygenase (IDO) expression was determined by immunohistochemistry in a consecutively selected cohort of 286 vulvar squamous carcinoma patients, all treated in the University Medical Center Groningen, the Netherlands. Associations between immunohistochemistry expression and the influence on survival were determined.
RESULTS: The number of tumor-infiltrating CD8(+) T-lymphocytes was significantly lower in tumors with loss of HLA-A (p=0.004), HLA-B/C (p=0.024) or β(2)-m (p=0.025) expression compared with tumors with expression of HLA class I. No association was found between the number of intratumoral CD8(+) T-lymphocytes and Foxp3(+) T-lymphocytes, HLA class I and IDO expression and survival of vulvar squamous carcinoma patients.
CONCLUSION: Our results indicate that the immune system does not seem to have a major influence on prognosis of patients with vulvar squamous carcinoma. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155674     DOI: 10.1016/j.ygyno.2011.12.416

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

2.  Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

Authors:  Ben C Creelan; Scott Antonia; Gerold Bepler; Timothy J Garrett; George R Simon; Hatem H Soliman
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

3.  PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Katarzyna Sznurkowska; Rafał Pęksa; Wojciech Biernat
Journal:  Oncotarget       Date:  2017-09-15

4.  Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Authors:  A Marijne Heeren; Ilse van Dijk; Daniella R A I Berry; Maryam Khelil; Debbie Ferns; Jeroen Kole; René J P Musters; Victor L Thijssen; Constantijne H Mom; Gemma G Kenter; Maaike C G Bleeker; Tanja D de Gruijl; Ekaterina S Jordanova
Journal:  Front Immunol       Date:  2018-07-11       Impact factor: 7.561

5.  High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Ziena Abdulrahman; Vanessa J van Ham; Marij van der Tol; Ilina Ehsan; Helena C van Doorn; Tjalling Bosse; Mariëtte I E van Poelgeest; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751

Review 6.  Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

Authors:  Fulvio Borella; Mario Preti; Luca Bertero; Giammarco Collemi; Isabella Castellano; Paola Cassoni; Stefano Cosma; Andrea Roberto Carosso; Federica Bevilacqua; Niccolò Gallio; Chiara Benedetto; Leonardo Micheletti
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

7.  Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Jacek Jan Sznurkowski; Anton Zawrocki; Wojciech Biernat
Journal:  Cancer Immunol Immunother       Date:  2013-12-25       Impact factor: 6.968

8.  Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Wojciech Biernat
Journal:  Oncotarget       Date:  2017-07-11

9.  Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.

Authors:  Thomas Hecking; Thore Thiesler; Glen Kristiansen; Kirsten Kübler; Cynthia Schiller; Jean-Marc Lunkenheimer; Tiyasha H Ayub; Andrea Rohr; Mateja Condic; Mignon-Denise Keyver-Paik; Rolf Fimmers; Jutta Kirfel; Walther Kuhn
Journal:  Oncotarget       Date:  2017-10-06

10.  Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.

Authors:  Martina Mandarano; Guido Bellezza; Maria Laura Belladonna; Jacopo Vannucci; Alessio Gili; Ivana Ferri; Chiara Lupi; Vienna Ludovini; Giulia Falabella; Giulio Metro; Giada Mondanelli; Rita Chiari; Lucio Cagini; Fabrizio Stracci; Fausto Roila; Francesco Puma; Claudia Volpi; Angelo Sidoni
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.